Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma

Arthritis Research and Therapy

Volumn 12, Issue 2, 2010, Pages

  Derrett Smith, Emma C ^a   Dooley, Audrey ^a   Khan, Korsa ^a   Shi wen, Xu ^a   Abraham, David ^a   Denton, Christopher P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; COLLAGEN; ENDOTHELIN; SMAD2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA DISEASE; AORTIC ADVENTITIAL FIBROSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; HEART MUSCLE FIBROSIS; MOUSE; MUSCLE CONTRACTILITY; NONHUMAN; PHENOTYPE; SCLERODERMA; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR DISEASE; VASCULAR FIBROSIS; ANIMAL; CELL CULTURE; DISEASE MODEL; DRUG EFFECT; FEMALE; FIBROSIS; GENETICS; MALE; METABOLISM; MUSCLE CONTRACTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; SYSTEMIC VASCULITIS; THORACIC AORTA; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; CELLS, CULTURED; COLLAGEN; DISEASE MODELS, ANIMAL; ENDOTHELINS; FEMALE; FIBROBLASTS; FIBROSIS; MALE; MICE; MICE, TRANSGENIC; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SYSTEMIC VASCULITIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77950787887     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2986     Document Type: Article

References (37)

1. Fleming JN, Schwartz SM. The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 2008, 34:41-55. vi, 10.1016/j.rdc.2008.01.001, 18329531.
2. Cheng KS, Tiwari A, Boutin A, Denton CP, Black CM, Morris R, Hamilton G, Seifalian AM. Carotid and femoral arterial wall mechanics in scleroderma. Rheumatology (Oxford) 2003, 42:1299-1305. 10.1093/rheumatology/keg371, 12777634.
3. Cheng KS, Tiwari A, Boutin A, Denton CP, Black CM, Morris R, Seifalian AM, Hamilton G. Differentiation of primary and secondary Raynaud's disease by carotid arterial stiffness. Eur J Vasc Endovasc Surg 2003, 25:336-341. 10.1053/ejvs.2002.1845, 12651172.
4. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, Stefanadis C, Mavrikakis M. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007, 56:1985-1993. 10.1002/art.22634, 17530638.
5. Moyssakis I, Gialafos E, Vassiliou V, Taktikou E, Katsiari C, Papadopoulos DP, Sfikakis PP. Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement. Rheumatology 2005, 44:251-254. 10.1093/rheumatology/keh478, 15546962.
6. Timár O, Soltész P, Szamosi S, Dér H, Szántó S, Szekanecz Z, Szücs G. Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis. J Rheumatol 2008, 35:1329-1333.
7. Akram MR, Handler CE, Williams M, Carulli M, Andron M, Black CM, Denton CP, Coghlan JG. Angiographically proven coronary artery disease in scleroderma. Rheumatology 2006, 45:1395-1398. 10.1093/rheumatology/kel120, 16606654.
8. Grainger D, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nature Medicine 1995, 1:74-79. 10.1038/nm0195-74, 7584958.
9. Leask A. Scar wars: is TGFβ the phantom menace in scleroderma?. Arthritis Res Ther 2006, 8:213-219. 10.1186/ar1976, 1779423, 16774692.
10. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003, 33:407-411. 10.1038/ng1116, 12598898.
11. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, Lauren Xu F, Myers LA, Spevak PJ, Cameron DE, De Backer J, Hellemans J, Chen Y, Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, De Paepe AM, Dietz HC. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005, 37:275-281. 10.1038/ng1511, 15731757.
12. Denton CP, Lindahl GE, Khan K, Shiwen X, Ong VH, Gaspar NJ, Lazaridis K, Edwards DR, Leask A, Eastwood M, Leoni P, Renzoni EA, Bou Gharios G, Abraham DJ, Black CM. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II TGFbeta receptor. J Biol Chem 2005, 280:16053-16065. 10.1074/jbc.M413134200, 15708853.
13. Antoniv TT, De Val S, Wells D, Denton CP, Rabe C, de Crombrugghe B, Ramirez F, Bou-Gharios G. Characterization of an evolutionarily conserved far-upstream enhancer in the human alpha 2(I) collagen (COL1A2) gene. J Biol Chem 2001, 276:21754-21764. 10.1074/jbc.M101397200, 11279244.
14. Denton CP, Zheng B, Shiwen X, Zhang Z, Bou-Gharios G, Eberspaecher H, Black CM, de Crombrugghe B. Activation of a fibroblast-specific enhancer of the proalpha2(I) collagen gene in tight-skin mice. Arthritis Rheum 2001, 44:712-722. 10.1002/1529-0131(200103)44:3<712::AID-ANR121>3.0.CO;2-1, 11263787.
15. Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, Lazaridis K, Abraham DJ, Black CM, de Crombrugghe B. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. J Biol Chem 2003, 278:25109-25119. 10.1074/jbc.M300636200, 12707256.
16. Denton CP, Khan K, Hoyles RK, Shiwen X, Leoni P, Chen Y, Eastwood M, David JA. Inducible lineage-specific deletion of Tβ RII in fibroblasts defines a pivotal regulatory role during adult skin wound healing. J Invest Dermatol 2009, 129:194-204. 10.1038/jid.2008.171, 18563179.
17. Rong JX, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci USA 2003, 100:13531-13536. 10.1073/pnas.1735526100, 263848, 14581613.
18. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3:RESEARCH0034. 12184808, 10.1186/gb-2002-3-7-research0034, 126239.
19. Hoyles RK, Khan K, Shiwen X, Howat SL, Lindahl GE, Leoni P, du Bois RM, Wells AU, Black CM, Abraham DJ, Denton CP. Fibroblast-specific perturbation of transforming growth factor beta signalling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum 2008, 58:1175-1188. 10.1002/art.23379, 18383385.
20. Machado FS, Desruisseaux Nagajyothi MS, Kennan RP, Hetherington HP, Wittner M, Weiss LM, Lee SC, Scherer PE, Tsuji M, Tanowitz HB. Endothelin in a murine model of cerebral malaria. Exp Biol Med (Maywood) 2006, 231:1176-1181.
21. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, Pearson JD, Dashwood M, du Bois RM, Black CM, Leask A, Abraham DJ. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004, 15:2707-2719. 10.1091/mbc.E03-12-0902, 420095, 15047866.
22. Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts. Arthritis Rheum 2007, 56:4189-4194. 10.1002/art.23134, 18050250.
23. Loop FT, Schaart G, Timmer ED, Ramaekers FC, van Eys GJ. Smoothelin, a novel cytoskeletal protein specific for smooth muscle cells. J Cell Biol 1996, 134:401-411. 10.1083/jcb.134.2.401, 2120883, 8707825.
24. Davenport AP, O'Reilly G, Kuc RE. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol 1995, 114:1110-1116. 1510347, 7620699.
25. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Xu SW, du Bois RM, Black CM. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997, 151:831-841. 1857854, 9284832.
26. Horstmeyer A, Licht C, Scherr G, Eckes B, Krieg T. Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta1. FEBS J 2005, 272:6297-6309. 10.1111/j.1742-4658.2005.05016.x, 16336267.
27. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001, 276:38121-38138. 10.1074/jbc.M008340200, 11457855.
28. Wunderlich C, Schober K, Schmeisser A, Heerwagen C, Tausche AK, Steinbronn N, Brandt A, Kasper M, Schwencke C, Braun-Dullaeus RC, Strasser RH. The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endothelium. J Mol Cell Cardiol 2008, 44:938-947. 10.1016/j.yjmcc.2008.02.275, 18417152.
29. Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, Vanpelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007, 56:334-344. 10.1002/art.22328, 17195237.
30. Akita M, Lee SH, Kaneko K. Electron microscopic observations of elastic fibres in the lung and aorta of tight-skin and beta-aminopropionitrile-fed mice. Histol Histopathol 1992, 7:39-45.
31. Marie I, Bény JL. Endothelial dysfunction in murine model of systemic sclerosis: tight-skin mice 1. J Invest Dermatol 2002, 119:1379-1387. 10.1046/j.1523-1747.2002.19614.x, 12485443.
32. Youssef P, Brama T, Englert H, Bertouch J. Limited scleroderma is associated with increased prevalence of macrovascular disease. J Rheumatol 1995, 22:469-472.
33. Ho ML, Veale D, Eastmond C, Nuki G, Belch J. Macrovascular disease and systemic sclerosis. Ann Rheum Dis 2000, 59:39-43. 10.1136/ard.59.1.39, 1752979, 10627425.
34. Chung AWY, Yang HHC, Yeung KA, van Breemen C. Mechanical and pharmacological approaches to investigate the pathogenesis of Marfan syndrome in the abdominal aorta. J Vasc Res 2008, 45:314-322. 10.1159/000113603, 18212506.
35. Bézie Y, Lacolley P, Laurent S, Gabella G. Connection of smooth muscle cells to elastic lamellae in aorta of spontaneously hypertensive rats. Hypertension 1998, 32:166-169.
36. Coghlan JG, Mukerjee D. The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opin Rheumatol 2001, 13:495-499. 10.1097/00002281-200111000-00008, 11698727.
37. Widmer CC, Mundy AL, Kretz M, Barton M. Marked heterogeneity of endothelin-mediated contractility and contraction dynamics in mouse renal and femoral arteries. Exp Biol Med (Maywood) 2006, 231:777-781.